

Resource Summary Report

Generated by PRECISE-TBI on Sep 7, 2026

MassLynx

RRID:SCR_014271

Type: Tool

Proper Citation

MassLynx (RRID:SCR_014271)

Resource Information

URL: http://www.waters.com/waters/en_US/MassLynx-MS-Software/nav.htm?cid=513662&locale=en_US

Proper Citation: MassLynx (RRID:SCR_014271)

Description: Software which can acquire, analyze, manage, and share mass spectrometry data. MassLynx controls any Waters mass spectrometry system, from sample and solvent management components to mass spectrometer and auxiliary detectors. The software can acquire nominal mass, exact mass, MS/MS and exact mass MS/MS data. The software system also maintains and consolidates all user sample data. Optional Application Manager programs provide additional information for specific MS analyses and data., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Synonyms: MassLynx MS Software

Resource Type: data acquisition software, data analysis software, data management software, data processing software, software application, software resource

Keywords: data acquisition software, data analysis software, data management software, mass spectrometry

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: MassLynx

Resource ID: SCR_014271

License URLs: http://www.waters.com/waters/en_US/Terms-of-Use/nav.htm?locale=en_US&cid=1000245 http://www.waters.com/waters/en_US/Site-Copyright/nav.htm?locale=en_US&cid=1001022

Record Creation Time: 20220129T080319+0000

Ratings and Alerts

No rating or validation information has been found for MassLynx .

No alerts have been found for MassLynx .

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 5809 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Lesire L, et al. (2026) Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma. British journal of pharmacology, 183(12), 3355.

Kawase M, et al. (2026) Phospholipid flippases ATP8A1 and ATP8A2 regulate GABAA receptor trafficking through distinct mechanisms in hippocampal neurons. iScience, 29(7), 116626.

Pan CH, et al. (2026) Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. Cancer research, 86(12), 2935.

Aufdermauer J, et al. (2026) Cancer-Associated BCL-2 Mutants Reveal Mechanisms Towards Venetoclax Resistance. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e76693.

Nikhil J, et al. (2026) Kynurenine Pathway Metabolite Levels in Drug Naïve and Risperidone Treated Schizophrenia: Insights From Systemic and Post-Mortem Brain Tissue Analysis. Journal of neurochemistry, 170(6), e70504.

Xiao W, et al. (2026) Metabolite-gated vascular contractility switch: OXGR1 activation mechanism enables agonist therapy for rosacea erythema. Cell, 189(7), 1990.

Tiwari D, et al. (2026) Molecular mechanisms of naturally encoded signaling bias at the complement anaphylatoxin receptors. Molecular cell, 86(13), 2586.

Zhen Q, et al. (2025) Erucic Acid, Derived by Lactobacillus Crispatus, Induces Ferroptosis in Cervical Cancer Organoids Through the PPAR-? Signaling Pathway. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(48), e12599.

Huang Y, et al. (2025) Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD. Cell reports. Medicine, 102522.

Petrova ZO, et al. (2025) The role of kinase domain dimerization in EGFR activation. Structure (London, England : 1993).

Guignet M, et al. (2025) Challenging the preclinical paradigm: Adverse effects of antiseizure medicines in male rats with drug-resistant epilepsy. British journal of pharmacology, 182(18), 4314.

Wang K, et al. (2025) Tobacco Smoking Rewires Cell Metabolism by Inducing GAPDH Succinylation to Promote Lung Cancer Progression. Cancer research, 85(15), 2838.

Jiang J, et al. (2025) Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism. Cell metabolism, 37(5), 1119.

Tsimberidou AM, et al. (2025) Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(6), 965.

Beck O, et al. (2025) Volumetric dried blood spots for determination of phosphatidylethanol: Validation of a liquid chromatography tandem massspectrometry method and clinical application. Drug testing and analysis, 17(2), 231.

Li Y, et al. (2025) Impaired microglial glycolysis promotes inflammatory responses after intracerebral haemorrhage via HK2-dependent mitochondrial dysfunction. Journal of advanced research, 73, 575.

Xiao B, et al. (2025) Treadmill exercise in combination with acousto-optic and olfactory stimulation improves cognitive function in APP/PS1 mice through the brain-derived neurotrophic factor- and Cygb-associated signaling pathways. Neural regeneration research, 20(9), 2706.

Maggadani BP, et al. (2025) CYP2D6 Genotyping for Optimization of Tamoxifen Therapy in Indonesian Women with ER+ Breast Cancer. Journal of personalized medicine, 15(3).

Wang X, et al. (2025) Explanation of the potential mechanism of Sophora flavescens Ait and processed products treating ulcerative colitis based on the analysis method of "chemical composition characterization-target prediction". RSC advances, 15(15), 11354.

Mehri S, et al. (2025) Identification of viral protease-dependent cleavage sites within the human astrovirus polyprotein. Journal of virology, 99(1), e0132124.